Search

• Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone

  Media

  Interim results from Part 1 of the RUBY clinical trial in primary advanced or recurrent endometrial cancer.

  https://www.gsk.com/en-gb/media/press-releases/phase-iii-ruby-clinical-trial-demonstrates-potential-of-jemperli-plus-chemotherapy-to-redefine-the-treatment-of-primary-advanced-or-recurrent-endometrial-cancer/

  First published: 27 March 2023

• Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia

  Media

  Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.

  https://www.gsk.com/en-gb/media/press-releases/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia/

  First published: 15 September 2023

• GSK highlights new data in non-small cell lung cancer and endometrial cancer at the European Society for Medical Oncology (ESMO) Congress 2023, reinforcing potential of Jemperli (dostarlimab) as a backbone immuno-oncology therapy

  Media

  Late-breaking data from head-to-head PERLA trial shows favourable numerical trend in overall survival (OS) results

  https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-new-data-in-non-small-cell-lung-cancer-and-endometrial-cancer-at-esmo/

  First published: 17 October 2023

• New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence

  Media

  A new GSK survey shows a large number of adults do not understand how shingles may be triggered.

  https://www.gsk.com/en-gb/media/press-releases/new-global-survey-finds-widespread-misunderstandings-about-shingles-despite-its-lifetime-prevalence/

  First published: 30 November 2023

• GSK’s Omjjara (momelotinib) approved in Japan for treatment of myelofibrosis

  Media

  Omjjara approved for use in both newly diagnosed or previously treated myelofibrosis patients.

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-omjjara-momelotinib-approved-in-japan-for-treatment-of-myelofibrosis/

  First published: 24 June 2024

• ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018

  Media

  ViiV, specialist HIV company will be presenting over 20 abstracts, including GEMINI 1 & 2 trials, at the AIDS 2018 in Amsterdam.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-at-aids-2018/

  First published: 18 July 2018

• ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen

  Media

  First phase III studies to show efficacy of two-drug regimen as maintenance therapy

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-results-from-first-phase-iii-studies-of-two-drug-hiv-treatment-regimen/

  First published: 19 December 2016

• Five inspirational organisations from Malawi, Bangladesh, Mali, Kenya, and Colombia recognised by GSK and Save the Children

  Media

  A simple low-cost device that helps newborn babies to breathe has been awarded $1million in the first GSK and Save the Children Award

  https://www.gsk.com/en-gb/media/press-releases/five-inspirational-organisations-from-malawi-bangladesh-mali-kenya-and-colombia-recognised-by-gsk-and-save-the-children/

  First published: 14 November 2013

• ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017

  Media

  ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-hiv-community-at-ias-2017/

  First published: 20 July 2017

• GSK to showcase scientific advances and progress in oncology at ASCO and EHA

  Media

  GSK will showcase innovative approaches to oncology R&D and cutting-edge science at the upcoming ASCO and EHA meetings.

  https://www.gsk.com/en-gb/media/press-releases/gsk-to-showcase-scientific-advances-and-progress-in-oncology-at-asco-and-eha/

  First published: 01 June 2021